GH Research rises as lead drug meets main goal in mid-stage studies

GH Research

10/01/2025 13:38

** Drug developer GH Research's  GHRS.O  shares rise 5.8% to
$9.5 premarket    
    ** Co says its lead experimental drug met the main goal in
two mid-stage studies testing it as a treatment for postpartum
depression and bipolar II disorder   
    ** The drug, GH001, helped significantly reduce severity of
depressive episodes and led to rapid antidepressant effect in
the studies - GHRS  
     ** In both trials, GH001 was well tolerated with no
reported treatment-related serious side-effects - GHRS
    ** Bipolar II disorder is a mental health condition that
causes extreme mood swings with at least one major depressive
episode and at least one hypomanic episode    
    ** Up to last close, stock up 54.3% over the past 12 months 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))